Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume – Here’s Why

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares saw unusually-strong trading volume on Monday . Approximately 190,046 shares were traded during mid-day trading, a decline of 9% from the previous session’s volume of 209,682 shares.The stock last traded at $11.49 and had previously closed at $12.59.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TLX shares. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday, September 14th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Tuesday, September 15th. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Finally, Royal Bank Of Canada lowered shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $20.40.

Telix Pharmaceuticals Stock Down 10.2%

The company’s 50 day moving average price is $11.30 and its 200 day moving average price is $10.35. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its stake in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares in the last quarter. XY Capital Ltd purchased a new stake in shares of Telix Pharmaceuticals in the first quarter valued at approximately $120,000. Lazard Asset Management LLC grew its holdings in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares during the period. Private Advisor Group LLC raised its position in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in Telix Pharmaceuticals in the second quarter worth $1,731,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.